NXGL Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2018βFY2025
Nexgel, Inc. had $11.4M of revenue in fiscal 2025, up 31.5% on the year before. Over five years, revenue changed +76.1% a year on average.
Last close Β· Oct 23, 2026
$5.03
5.7%Hi! I read Nexgel, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+31.5%
Yes. Sales grew 31.5% last year.
Does it make a profit?
β26.3%
No. It lost money last year.
Does profit turn into cash?
β12.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Nexgel, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 10, 2026
Tuesday Β· in 15 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 17, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 14, 2026 | Q1 '26 | After the market closes | 10-Q β |
| Mar 31, 2026 | Q4 '25 | After the market closes | 10-K β |
| Nov 11, 2025 | Q3 '25 | Time not announced | 8-K β |
| Aug 12, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 13, 2025 | Q1 '25 | After the market closes | 8-K β |
| Jan 22, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Oct 10, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Nexgel, Inc. had $11.4M of revenue in fiscal 2025, up 31.5% on the year before. Over five years, revenue changed +76.1% a year on average. Its operating margin was β29.3%, up 11.6Β pts: of every 100 in sales, about β29 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Nexgel, Inc. lost $3.0M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$1.4M in fiscal 2025, β12.1% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Nexgel, Inc. owes $0.6M more than it holds in cash.
Cash, debt and the ratios that show how comfortably Nexgel, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $13.4M | $6.6M | $2.7M | $1.8M | $0.3M |
| Debt incl. finance leases | β | $0.3M | $0.8M | $1.1M | $0.9M |
| Debt / equity | β | 0.0x | 0.2x | 0.1x | 0.1x |
| Interest coverage | β | β2.5x | β231.8x | β43.9x | β98.6x |
| Current ratio | 4.8x | 8.7x | 2.0x | 2.1x | 1.5x |
| Quick ratio | 4.7x | 8.2x | 1.5x | 1.4x | 0.8x |
| Total assets | $17.0M | $10.4M | $10.0M | $11.0M | $10.5M |
| Total liabilities | $4.9M | $2.7M | $4.8M | $4.9M | $5.6M |
| Shareholders' equity | $12.1M | $7.6M | $4.7M | $5.8M | $4.5M |
| Net debt (β = net cash) | β | β$6.3M | β$1.9M | β$0.8M | $0.6M |
KIRA Β· Its return on capital was β56.0%: every 100 invested in the business earned about β56 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Nexgel, Inc. passes 5 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 8 | 3 / 8 | 4 / 8 | 4 / 8 | 2 / 9 | 5 / 9 | 5 / 9 |
| Accruals ratio | β46.5% | β8.3% | β22.3% | β16.2% | β12.8% | 0.8% | 5.6% | β15.8% |
| Altman Z'' | β16.93 | β7.98 | β13.13 | 4.53 | 1.35 | β4.49 | β4.70 | β6.99 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.2M | $0.7M | $0.7M | $1.6M | $2.0M | $4.1M | $8.7M | $11.4M |
| Gross profit | $0.5M | β$0.1M | β$0.3M | $0.0M | $0.3M | $0.4M | $2.7M | $4.5M |
| Research and development | β | β | β | $0.0M | $0.4M | $0.1M | $0.1M | $0.0M |
| Operating income | β$1.9M | β$1.9M | β$2.3M | β$2.6M | β$3.3M | β$3.5M | β$3.6M | β$3.4M |
| Interest expense | β | β | β | β | $1.3M | $0.0M | $0.1M | $0.0M |
| Pretax income | β | β | β | β | β$4.7M | β$3.2M | β$3.5M | β$2.9M |
| Income tax | β | $0.0M | $0.0M | $0.0M | $0.0M | β | β | β |
| Net income | β$1.9M | β$1.9M | β$2.3M | β$4.3M | β$4.7M | β$3.2M | β$3.3M | β$3.0M |
| Diluted EPS | β$0.38 | β$0.14 | β$1.05 | β$1.45 | β$0.85 | β$0.56 | β$0.50 | β$0.38 |
| Diluted shares | 0.01B | 0.01B | 0.00B | 0.00B | 0.01B | 0.01B | 0.01B | 0.01B |
| Cash flow | ||||||||
| Cash from operations | β$1.5M | β$1.8M | β$1.8M | β$2.8M | β$3.0M | β$3.2M | β$3.9M | β$1.3M |
| Capital expenditure | β | $0.0M | $0.3M | $0.3M | $0.1M | $0.7M | $0.4M | $0.1M |
| Free cash flow | β | β$1.8M | β$2.1M | β$3.0M | β$3.1M | β$3.9M | β$4.3M | β$1.4M |
| Depreciation and amortization | $0.3M | $0.1M | $0.1M | $0.1M | $0.1M | $0.2M | $0.4M | $0.5M |
| Stock-based compensation | $0.0M | $0.0M | $0.2M | $0.3M | $0.3M | $0.2M | $0.4M | $0.7M |
| Acquisitions | β | β | β | β | β | $0.5M | β | β |
| Balance sheet | ||||||||
| Cash and short-term investments | $0.0M | $0.3M | $0.0M | $13.4M | $6.6M | $2.7M | $1.8M | $0.3M |
| Total debt | β | β | β | β | $0.3M | $0.8M | $0.7M | $0.6M |
| Finance lease liabilities | β | β | β | β | β | β | $0.4M | $0.3M |
| Current assets | $0.4M | $0.5M | $0.4M | $13.9M | $7.5M | $5.1M | $5.1M | $4.3M |
| Current liabilities | $0.4M | $0.8M | $1.3M | $2.9M | $0.9M | $2.5M | $2.5M | $3.0M |
| Inventory | $0.1M | $0.1M | $0.2M | $0.3M | $0.5M | $1.3M | $1.8M | $2.1M |
| Property and equipment, net | $0.3M | $0.3M | $0.6M | $0.7M | $0.7M | $1.5M | $2.2M | $2.0M |
| Goodwill | β | $0.0M | $0.3M | $0.3M | $0.3M | $1.1M | $1.1M | $1.1M |
| Intangible assets | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.3M | $0.8M | $0.7M |
| Total assets | $0.7M | $1.9M | $2.3M | $17.0M | $10.4M | $10.0M | $11.0M | $10.5M |
| Total liabilities | $0.5M | $1.5M | $2.2M | $4.9M | $2.7M | $4.8M | $4.9M | $5.6M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | β | β | β | β |
| Shareholders' equity | $0.3M | $0.4M | $0.1M | $12.1M | $7.6M | $4.7M | $5.8M | $4.5M |
| Margins | ||||||||
| Gross margin | 23.2% | β19.1% | β43.2% | 0.5% | 12.5% | 9.1% | 31.6% | 39.5% |
| Operating margin | β85.3% | β268.3% | β335.3% | β165.7% | β163.5% | β85.0% | β40.9% | β29.3% |
| EBITDA margin | β70.8% | β259.0% | β327.9% | β158.4% | β158.0% | β79.5% | β35.9% | β25.4% |
| Net margin | β85.3% | β268.2% | β335.9% | β277.9% | β231.7% | β77.2% | β37.8% | β26.3% |
| FCF margin | β | β253.0% | β313.5% | β194.8% | β150.8% | β96.2% | β49.6% | β12.1% |
| Returns | ||||||||
| Return on capital | β | β | β | β | β201.7% | β96.9% | β60.6% | β56.0% |
| Return on capital employed | β568.7% | β176.5% | β244.3% | β18.2% | β35.2% | β46.9% | β41.7% | β44.7% |
| Return on equity | β671.9% | β581.8% | β1,004.0% | β70.9% | β48.1% | β51.2% | β62.8% | β58.7% |
| Return on assets | β255.5% | β146.3% | β109.2% | β44.8% | β34.7% | β31.1% | β31.3% | β28.0% |
| Return on tangible equity | β671.9% | β506.1% | β | β36.7% | β65.0% | β97.3% | β85.9% | β113.2% |
| Growth | ||||||||
| Revenue growth | β | β67.6% | β6.0% | 130.1% | 32.0% | 99.7% | 112.5% | 31.5% |
| Share count change | β | 171.1% | β83.4% | 32.2% | 87.1% | 1.7% | 14.8% | 20.6% |
| Financial health | ||||||||
| Debt / equity | β | β | β | β | 0.0x | 0.2x | 0.1x | 0.1x |
| Interest coverage | β | β | β | β | β2.5x | β231.8x | β43.9x | β98.6x |
| Current ratio | 0.9x | 0.6x | 0.3x | 4.8x | 8.7x | 2.0x | 2.1x | 1.5x |
| Quick ratio | 0.6x | 0.5x | 0.1x | 4.7x | 8.2x | 1.5x | 1.4x | 0.8x |
| Capital allocation | ||||||||
| Capex / revenue | β | 0.0% | 46.3% | 17.3% | 4.7% | 17.0% | 5.1% | 0.6% |
| Stock comp / revenue | 0.0% | 0.6% | 34.4% | 18.4% | 14.6% | 5.3% | 4.2% | 5.7% |
| Quality scores | ||||||||
| Piotroski F-score | β | 2.0 | 3.0 | 4.0 | 4.0 | 2.0 | 5.0 | 5.0 |
| Altman Z'' | β16.9 | β8.0 | β13.1 | 4.5 | 1.3 | β4.5 | β4.7 | β7.0 |
| Accruals ratio | β46.5% | β8.3% | β22.3% | β16.2% | β12.8% | 0.8% | 5.6% | β15.8% |
Source: SEC EDGAR XBRL filings (CIK 0001468929). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
